INT205603

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.16
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 4.84
Pain Relevance 0.15

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Pdgfa) extracellular region (Pdgfa)
Anatomy Link Frequency
platelet 2
mesenchymal cells 1
Pdgfa (Mus musculus)
Pain Link Frequency Relevance Heat
fibrosis 101 97.00 Very High Very High Very High
antagonist 4 16.80 Low Low
Arthritis 1 10.24 Low Low
imagery 49 5.00 Very Low Very Low Very Low
cytokine 22 5.00 Very Low Very Low Very Low
Inflammation 18 5.00 Very Low Very Low Very Low
positron emission tomography 14 5.00 Very Low Very Low Very Low
Taxol 14 5.00 Very Low Very Low Very Low
chemokine 8 5.00 Very Low Very Low Very Low
Inflammatory response 5 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cancer 342 98.68 Very High Very High Very High
Pulmonary Fibrosis 68 97.00 Very High Very High Very High
Apoptosis 49 95.80 Very High Very High Very High
Fibrosis 58 93.32 High High
Colon Cancer 6 93.32 High High
Targeted Disruption 8 88.44 High High
Hyperplasia 1 86.00 High High
Hematologic Neoplasms 2 77.80 Quite High
Death 5 76.88 Quite High
Cicatrix 2 76.40 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The effect of PDGF and VEGF receptor inhibitors on tumor vessel leakiness was determined by injection of Evans blue, a dye that quantitatively binds to albumin in the circulation.
Regulation (effect) of PDGF associated with cancer
1) Confidence 0.16 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2781164 Disease Relevance 1.07 Pain Relevance 0
Because PDGF is a key mitogen and chemoattractant for mesenchymal cells, targeting PDGF or its receptors could be effective in limiting the replication of these cells and reducing collagen deposition and matrix formation.
Regulation (targeting) of PDGF in mesenchymal cells
2) Confidence 0.14 Published 2010 Journal Fibrogenesis Tissue Repair Section Body Doc Link PMC2940818 Disease Relevance 0.93 Pain Relevance 0.15
The anti-tumor activity of SU6668 has been attributed to its antiangiogenic potential arising from its inhibitory effect on the receptor-tyrosine kinase activity of VEGF, FGF, and PDGF.
Regulation (effect) of PDGF associated with cancer
3) Confidence 0.13 Published 2007 Journal BMC Cancer Section Body Doc Link PMC1832206 Disease Relevance 1.98 Pain Relevance 0
Sunitinib and sorafenib are multitargeting TKIs that can block activity angiogenic targets such as of VEGFR1, 2, 3, platelet-derived growth factor (PDGF) receptors and c-Kit or RET.
Regulation (targets) of platelet-derived growth factor in platelet
4) Confidence 0.04 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2902148 Disease Relevance 0.43 Pain Relevance 0
Sunitinib and sorafenib are multitargeting TKIs that can block activity angiogenic targets such as of VEGFR1, 2, 3, platelet-derived growth factor (PDGF) receptors and c-Kit or RET.
Regulation (targets) of PDGF in platelet
5) Confidence 0.04 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2902148 Disease Relevance 0.43 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox